Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An <i>In Vitro</i> Study.

Front Immunol · 2021 · PMC8712887 · PMID 34970256

Europe PMC DOI

hedged sentence

0.0430

closest p · 0.9× alpha

0.0430

boldest claim

The sentences

a weakly significant differencep =0.043actually significant

CD3+IFNγ+ cells from RRMS patients proliferated until day 7, with a weakly significant difference observed between exposed and unexposed cells ( p =0.043).

also in 56 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.